CONy 2020 Plenary Program

  • Home
  • CONy 2020 Plenary Program

*This program is subject to change

Thursday, March 26, 2020
09:00-11:00 SESSION 1 | OPENING SESSION
09:00-09:30 Welcome remarks
Amos Korczyn, Israel
09:30-10:00 PD from mitochondria to lysosomes and on to therapy
Anthony Schapira, UK
10:00-10:30  
10:30-11:00 Should cannabinoids be legally available to the public?
Peter Feldschreiber, UK
11:00-11:30 Coffee Break
11:30-13:00 SESSION 2 | PLENARY LECTURES
11:30-12:00 Neurostimulation and its potential to improve learning and cognition in health and disease
Roi Cohen Kadosh, UK
12:00-12:30 Emerging neuropathological comorbidities in aging – LATE, ARTAG and CTE
Lea Grinberg, USA/Brazil
12:30-13:00 Pathological impulsivity – a neurobehavioural phenomenon
Valerie Voon, UK
13:00-13:45 Lunch Break
13:45-15:15 SESSION 3 | PLENARY LECTURES
13:45-14:15 GAD antibodies spectrum disorder
Marinos Dalakas, USA
14:15-14:45 MS is one disease; why definitions matter to patients and how we treat them
Gavin Giovannoni, UK
14:45-15:15 Digital health technologies in clinical care and clinical trials
15:15-15:30 Coffee Break
15:30-18:00 SESSION 4 | PLENARY LECTURES
15:30-16:00  
16:00-16:30 The two in one brain circulations
Vladimir Hachinski, Canada
16:30-17:00 Functional neurological disorders
Stoyan Popkirov, Germany
17:00-18:00 GWAS is likely to contribute significantly to Alzheimer disease  (AD) patients care
  Capsule: Genome-wide association studies (GWAS) looking at genetic variants in different individuals may identify variants associated with disease. These cross-national investigations have been applied widely to AD, identifying dozens of “disease-specific” alterations. Is the huge and expensive investment likely to help find a cure for AD?
17:00-17:15 Host:
17:15-17:30 Yes: John Hardy, UK
17:30-17:45 No: Amos Korczyn, Israel
17:45-18:00 Discussions and rebuttals
18:00-18:30 OPENING CEREMONY
18:00-18:30 Thomas Willis and the first decade of the brai
Alastair Compston, UK